Esperion Therapeutics Inc (NASDAQ:ESPR) rose 6.4% during mid-day trading on Monday after Deutsche Bank raised their price target on the stock to $100.00. Deutsche Bank currently has a buy rating on the stock. Esperion Therapeutics traded as high as $81.29 and last traded at $80.05. Approximately 1,629,134 shares traded hands during mid-day trading, an increase of 151% from the average daily volume of 649,217 shares. The stock had previously closed at $75.26.
ESPR has been the subject of a number of other reports. Chardan Capital reaffirmed a “neutral” rating and issued a $75.00 price objective (up from $20.00) on shares of Esperion Therapeutics in a research report on Tuesday, December 5th. Credit Suisse Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 price objective for the company. Stifel Nicolaus set a $105.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 15th. BidaskClub raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 13th. Finally, Northland Securities reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a research report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $87.36.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the business’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $71.79, for a total value of $838,076.46. Following the transaction, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 32.50% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. Swiss National Bank boosted its stake in Esperion Therapeutics by 30.4% in the third quarter. Swiss National Bank now owns 34,300 shares of the biopharmaceutical company’s stock valued at $1,719,000 after acquiring an additional 8,000 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in Esperion Therapeutics by 14.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 80,000 shares of the biopharmaceutical company’s stock valued at $4,010,000 after acquiring an additional 10,000 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Esperion Therapeutics by 12,603.4% in the third quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock valued at $10,098,000 after acquiring an additional 199,890 shares during the last quarter. Rhumbline Advisers boosted its stake in Esperion Therapeutics by 10.6% in the third quarter. Rhumbline Advisers now owns 20,500 shares of the biopharmaceutical company’s stock valued at $1,027,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Esperion Therapeutics by 8.3% in the third quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock valued at $1,257,000 after acquiring an additional 1,913 shares during the last quarter. Hedge funds and other institutional investors own 91.69% of the company’s stock.
The company has a market capitalization of $2,070.00, a P/E ratio of -11.12 and a beta of 2.45.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.36. During the same quarter in the previous year, the firm earned ($1.29) EPS. sell-side analysts anticipate that Esperion Therapeutics Inc will post -5.66 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/03/14/esperion-therapeutics-espr-stock-price-up-6-4-after-analyst-upgrade.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.